for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cue Biopharma Inc

CUE.OQ

Latest Trade

12.68USD

Change

-0.03(-0.24%)

Volume

7,543

Today's Range

12.63

 - 

12.94

52 Week Range

4.16

 - 

13.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.71
Open
12.64
Volume
7,543
3M AVG Volume
2.78
Today's High
12.94
Today's Low
12.63
52 Week High
13.12
52 Week Low
4.16
Shares Out (MIL)
22.99
Market Cap (MIL)
292.26
Forward P/E
-7.32
Dividend (Yield %)
--

Latest Developments

More

Cue Biopharma Reports Third Quarter 2019 Financial Results

Cue Biopharma Qtrly Loss Per Share $0.31

Cue Biopharma Promotes Dr. Anish Suri To President And CSO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cue Biopharma Inc

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

Industry

Biotechnology & Drugs

Contact Info

21 Erie St

+1.617.9492680

https://www.cuebiopharma.com/

Executive Leadership

Barry J. Simon

Independent Chairman of the Board

Anish Suri

President, Chief Scientific Officer

Daniel R. Passeri

Chief Executive Officer, Director

Rodolfo J. Chaparro

Executive Vice President - Head of Immunology

Ronald D. Seidel

Executive Vice President - Head of Research and Development

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-1.940

2019(E)

-1.720
Price To Earnings (TTM)
--
Price To Sales (TTM)
106.68
Price To Book (MRQ)
10.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-106.17
Return on Equity (TTM)
-87.76

Latest News

Latest News

BRIEF-Peter Appel Reports Passive Stake Of 7.6 Pct In Cue Biopharma

* PETER APPEL REPORTS A PASSIVE STAKE OF 7.6 PERCENT IN CUE BIOPHARMA INC AS OF DEC 27, 2017 - SEC FILING Source text: (http://bit.ly/2BWquxU) Further company coverage:

BRIEF-Mark Strome Reports 5.7 Pct Passive Stake In Cue Biopharma

* MARK STROME REPORTS A 5.7 PERCENT PASSIVE STAKE IN CUE BIOPHARMA INC AS OF DECEMBER 27, 2017- SEC FILING Source: (http://bit.ly/2AIDG48) Further company coverage:

BRIEF-Cue Biopharma sees IPO of up to 8 mln shares of its common stock priced at $7.50/shr

* CUE BIOPHARMA INC SEES IPO OF UP TO 8 MILLION SHARES OF ITS COMMON STOCK PRICED AT $7.50 PER SHARE - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up